Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

Abstract Background The third generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) osimertinib has been initially approved for T790M positive Non-Small Cell Lung Cancer (NSCLC) and more recently for first-line treatment of EGFR-mutant T790M negative NSCLC patients. Simi...

Full description

Bibliographic Details
Main Authors: Silvia La Monica, Roberta Minari, Daniele Cretella, Lisa Flammini, Claudia Fumarola, Mara Bonelli, Andrea Cavazzoni, Graziana Digiacomo, Maricla Galetti, Denise Madeddu, Angela Falco, Costanza Annamaria Lagrasta, Anna Squadrilli, Elisabetta Barocelli, Alessandro Romanel, Federico Quaini, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Non-Small Cell Lung Cancer
Osimertinib
Resistance
Epidermal Growth Factor Receptor
Pemetrexed
Cisplatin
Online Access:http://link.springer.com/article/10.1186/s13046-019-1240-x

Internet

http://link.springer.com/article/10.1186/s13046-019-1240-x

Similar Items